Keytruda (Pembrolizumab)
Search more drugs→What is Keytruda (Pembrolizumab)?
Keytruda, known generically as Pembrolizumab, is a monoclonal antibody used in cancer immunotherapy. It is pronounced as "pem-bro-li-zoo-mab" and falls under the class of drugs known as immune checkpoint inhibitors. Keytruda is available by prescription and is administered via intravenous infusion. It is marketed under the brand name Keytruda and is used to treat various types of cancer by enhancing the body's immune response against cancer cells.
What conditions or symptoms is Keytruda (Pembrolizumab) used to treat?
Keytruda is primarily used to treat several types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and urothelial carcinoma, among others. It works by targeting the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to fight cancer. If you are experiencing symptoms such as unexplained weight loss, persistent cough, or unusual lumps, please check them here:Check your unexplained weight loss, persistent cough, or unusual lumps symptoms here.
How does Keytruda (Pembrolizumab) work in the body?
Keytruda functions by blocking the programmed death receptor-1 (PD-1) pathway. This pathway, when activated, inhibits the immune system's ability to attack cancer cells. By blocking PD-1, Keytruda enhances the immune system's response against cancer cells, allowing it to recognize and destroy them more effectively. This mechanism of action is crucial in treating cancers that have evaded the immune system's detection.
In what forms is Keytruda (Pembrolizumab) available?
Keytruda is available as a solution for intravenous infusion. It is supplied in single-dose vials containing either 50 mg or 100 mg of Pembrolizumab. The solution is clear to slightly opalescent, colorless to slightly yellow, and should be administered by a healthcare professional in a clinical setting. The dosage and frequency of administration depend on the type of cancer being treated and the patient's overall health condition.
What are the most common side effects of Keytruda (Pembrolizumab)?
Common side effects of Keytruda include fatigue, nausea, itching, rash, decreased appetite, and constipation. Patients may also experience diarrhea, cough, and joint pain. These side effects are generally mild to moderate in severity and can often be managed with supportive care. It is important for patients to report any persistent or bothersome side effects to their healthcare provider.
What are the serious or severe side effects of Keytruda (Pembrolizumab)?
Serious side effects of Keytruda can include immune-mediated reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis. These reactions occur when the immune system attacks normal organs and tissues. Symptoms of severe side effects may include difficulty breathing, severe abdominal pain, yellowing of the skin or eyes, and extreme fatigue. Immediate medical attention is necessary if any of these symptoms occur.
How should Keytruda (Pembrolizumab) be stored safely?
Keytruda should be stored in a refrigerator at temperatures between 2°C to 8°C (36°F to 46°F) and protected from light. It should not be frozen or shaken. The vial should be kept in its original carton until it is ready to be used to protect it from light. Once diluted, the solution can be stored at room temperature for up to 6 hours or refrigerated for up to 24 hours before administration.
What are the overall side effects of Keytruda (Pembrolizumab)?
The overall side effects of Keytruda include both common and serious adverse reactions. Common side effects are generally mild and manageable, while serious side effects require immediate medical attention. Patients should be closely monitored for signs of immune-mediated reactions and other severe side effects. It is crucial for patients to communicate any unusual symptoms to their healthcare provider promptly.
What warnings or precautions should be considered when taking Keytruda (Pembrolizumab)?
Patients should be aware of the potential for immune-mediated side effects and the need for close monitoring during treatment with Keytruda. It is important to inform healthcare providers of any pre-existing conditions, such as autoimmune disorders, as these may be exacerbated by treatment. Additionally, patients should be advised to report any new or worsening symptoms immediately to their healthcare provider.
Who should avoid using Keytruda (Pembrolizumab)?
Keytruda should be avoided by individuals with a known hypersensitivity to Pembrolizumab or any of its components. Patients with active autoimmune diseases or those requiring immunosuppressive therapy may not be suitable candidates for Keytruda. It is essential for healthcare providers to evaluate each patient's medical history and current health status before initiating treatment with Keytruda.
What important information should I know before using Keytruda (Pembrolizumab)?
Before starting Keytruda, patients should be informed about the potential risks and benefits of the treatment. They should understand the importance of adhering to scheduled infusions and attending all follow-up appointments. Patients should also be educated about the signs and symptoms of immune-mediated side effects and the importance of reporting these symptoms promptly to their healthcare provider.
What should I discuss with my healthcare provider before starting Keytruda (Pembrolizumab)?
Patients should discuss their complete medical history with their healthcare provider, including any history of autoimmune diseases, organ transplants, or previous cancer treatments. It is also important to discuss any current medications, including over-the-counter drugs and supplements, as these may interact with Keytruda. Patients should inform their provider of any planned surgeries or vaccinations during treatment.
Does Keytruda (Pembrolizumab) interact with any foods or beverages?
There are no specific food or beverage interactions known with Keytruda. However, patients should maintain a balanced diet and stay hydrated during treatment. It is always advisable to discuss dietary habits with a healthcare provider to ensure optimal health and well-being while undergoing cancer treatment.
Does Keytruda (Pembrolizumab) have interactions with other medications?
Keytruda may interact with other medications, particularly those that suppress the immune system. Patients should provide a complete list of all medications they are taking to their healthcare provider. This includes prescription drugs, over-the-counter medications, and dietary supplements. The healthcare provider will assess potential interactions and adjust treatment plans accordingly.
What should I do if I accidentally take too much Keytruda (Pembrolizumab)?
Since Keytruda is administered by a healthcare professional in a clinical setting, the risk of overdose is minimal. However, in the event of an overdose, patients should seek immediate medical attention. Symptoms of overdose may include an exacerbation of side effects such as fatigue, nausea, or immune-mediated reactions. Prompt medical intervention is crucial to manage any adverse effects.
What should I do if I miss a dose of Keytruda (Pembrolizumab)?
If a dose of Keytruda is missed, patients should contact their healthcare provider as soon as possible to reschedule the infusion. It is important to adhere to the treatment schedule to maintain the effectiveness of the therapy. Patients should not attempt to self-administer the medication or adjust the dosing schedule without consulting their healthcare provider.
What signs or symptoms should I watch for while taking Keytruda (Pembrolizumab)?
Patients should be vigilant for signs of immune-mediated side effects, such as difficulty breathing, severe abdominal pain, or jaundice. Other symptoms to watch for include new or worsening cough, diarrhea, or skin rashes. Any unusual or severe symptoms should be reported to a healthcare provider immediately, as early intervention can prevent complications.
When was Keytruda (Pembrolizumab) first developed and approved by the FDA?
Keytruda was first developed by Merck & Co., Inc. and received its initial approval from the U.S. Food and Drug Administration (FDA) in September 2014. It was approved for the treatment of advanced melanoma and has since gained approval for multiple other cancer types. The development and approval of Keytruda marked a significant advancement in cancer immunotherapy, offering new hope for patients with difficult-to-treat cancers.